Asian Pacific Journal of Cancer Prevention

  • 제15권19호
  • /
  • Pages.8483-8488
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Predictive Factors of Survival Time of Breast Cancer in Kurdistan Province of Iran between 2006-2014: A Cox Regression Approach

  • Karimi, Asrin (Department of Epidemiology, Faculty of Health, Ilam University of Medical Sciences) ;
  • Delpisheh, Ali (Department of Epidemiology, Faculty of Health, Ilam University of Medical Sciences) ;
  • Sayehmiri, Kourosh (Prevention of Psychosocial Injuries Foundation, Research Center) ;
  • Saboori, Hojjatollah (Department of Radiation-Oncology, Towhid Hospital) ;
  • Rahimi, Ezzatollah (Department of Radiation-Oncology, Towhid Hospital)
  • 발행 : 2014.10.23
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Breast cancer is the most common cancer and the second most common cause of cancer-induced mortalities in Iranian women, following gastric carcinoma. The survival of these patients depends on several factors, which are very important to identify in order to understand the natural history of the disease. Materials and Methods: In this retrospective study, 313 consecutive women with pathologically-proven diagnosis of breast cancer who had been treated during a seven-year period (January 2006 until March 2014) at Towhid hospital, Sanandaj city, Kurdistan province of Iran, were recruited. The Kaplan-Meier method was used for data analysis, and finally those factors that showed significant association on univariate analysis were entered in a Cox regression model. Results: the mean age of patients was $46.10{\pm}10.81$ years. Based on Kaplan-Meier method median of survival time was 81 months and 5 year survival rate was $75%{\pm}0.43$. Tumor metastasis (HR=9.06, p=0.0001), relapse (HR=3.20, p=0.001), clinical stage of cancer (HR=2.30, p=0.03) and place of metastasis (p=0.0001) had significant associations with the survival rate variation. Patients with tumor metastasis had the lowest five-year survival rate (37%)and among them patients who had brain metastasis were in the worst condition (5 year survival rate= $11%{\pm}0.10$). Conclusions: Our findings support the observation that those women with higher stages of breast malignancies (especially with metastatic cancer) have less chance of surviving the disease. Furthermore, screening programs and early detection of breast cancer may help to increase the survival of those women who are at risk of breast cancer.

키워드

참고문헌

  1. American joint committee on cancer AJCC Cancer staging mannual (2002). 3 Ed, New York-Berlin: Springer-Verlag.
  2. Akbari M, Mirzaei H, Souri H (2007). 5-year survival of breast cancer in shoada-e-tajrish and jorjani hospitals. Hakim Res J, 9, 39-44.
  3. Akhsan A, Aryandono T (2010). Prognostic factors of locally advanced breast cancer patients receiving neoadjuvant and adjuvant chemotherapy. Asian Pac J Cancer, 11, 759-61.
  4. Akhavan A, Binesh F, Heidari S (2014). Survival of brain metastatic patients in Yazd. Asian Pac J Cancer Prev, 15, 3571-4. https://doi.org/10.7314/APJCP.2014.15.8.3571
  5. Branicadi F, Chales A, Dana K, Biliary R, Schwartz S (2005). Principle of surgery. 8th ed. New York: McGraw-Hill, Medical Publishing Division.
  6. Berrino F, Angelis RD, Sant M, et al (2007). Survival for eight major cancers combined for European adults diagnosed in 1995-99: results of th FUROCARE -4 study. Lancet Oncol, 8, 773-83. https://doi.org/10.1016/S1470-2045(07)70245-0
  7. Dawood S, Broglio K, Esteva FJ, et al (2008). Deffinig prognosis for women with Breast cancer and CNS metastasis by HER-2 status. Ann Ancol, 19, 1272-48.
  8. Ederer F, Axtell LM, Cutler SJ (1961). The relative survival rate: A statistical methodology. Natl cancer Inst Monogr, 6, 101-21.
  9. Esteve J, Benhamou E, Croasdale M, Raymond L (1990). Relative survival and the estimation of net survival: Element for further discussion. Stat Med, 9, 529-38. https://doi.org/10.1002/sim.4780090506
  10. Hosmer DW, Lemeshow S (1999). Applied Survival Analysis: Regression Modeling of Time to Event Data, New York John Wiley & Sons.
  11. Horita K, Yamagoush A, Hirose K, et al (2001). Pronostic Factor affecting disease free Survival rate following surgical resection of primary Breast cancer. Eur J Histochem, 45, 73-84.
  12. International Agency for Research on Cancer (2006). Cancer Mondial [on line database]. Available from: URL: http //WWW-dep.iarc.fr/ Accessed Dec 7.
  13. Klein JP, Moeschberger ML (1997). Survival analysis techniques for censored and truncated data, New York: Springer-Verlag.
  14. Korizumi M, Yoshimoto M, Kasumi F, Iwase T (2010). An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC Cancer, 10, 381-85. https://doi.org/10.1186/1471-2407-10-381
  15. Khodabakhshi R, Gohari M, Moghadami Fard Z, Foadzi H, Vahabi N (2011a). Disease- Free survival breast cancer patients and identitification of related factors. Razi J Med Sci, 18, 27-32.
  16. Khodabakhshi R, Gohari MR, Moghadami Fard Z, Foadzi H, Vahabi N (2011b). Disease-free survival of breast cancer patients and identification of related factors. Razi journal of Medical Sciences, 18, 27-32.
  17. Kaviani A, Neishaboury MR, Mohammadzadeh N, et al (2013). Effects of obesity on presentation of breast cancer, lymph node metastasis and patients survival: A retrospective review. Asian Pac J Cancer Prev, 14, 2225-9. https://doi.org/10.7314/APJCP.2013.14.4.2225
  18. Moran JL, Bersten AD, Solomon PJ, Edibam C, Hunt T (2008a). Modelling survival in acute severe illness: Cox versus accelerated failure time model. J Eval Clin Pract, 14, 83-93. https://doi.org/10.1111/j.1365-2753.2007.00806.x
  19. Moradi Marjaneh M, Homaei F, Shamsiyan A, et al (2008b). Relationship between HER-2, P53, Estrogen receptor, progestron receptor and survival rate in Iranian women with breast cancer, 1, 7-17.
  20. Mohagheghi MA, Mosavi-Jarrahi A, Malekzade R, et al (2009). Cancer incidence in tehran metropolis: the first report from the tehran population-based cancer rigestery 1998-2001. Arch Iran Med, 12, 15-23.
  21. Nicholas EM, Patchell RA, Regine WF, Kwok Y (1766). Palliation of brain and spinal cord metastases. in perez and bradys principles and practice of radiation oncology, USA, 6th. Edition page.
  22. Nor Aini A, Wan R, Nor Asia M, et al (2013a). Survival rate of breast cancer patients in Malasiya: a population-based Study. Asian Pac J Cancer Prev, 14, 4591-4. https://doi.org/10.7314/APJCP.2013.14.8.4591
  23. Najafi B, Anvari S, Atrkar Roshan Z (2013). Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2010 in Iran. Asian Pac J Cancer Prev, 14, 5811-6. https://doi.org/10.7314/APJCP.2013.14.10.5811
  24. Orbe J, Ferriera E, Nunez-Anton V (2002). Comparing proportional hazards and accelerated failure time models for survival analysis. Stat Med, 21, 3493-510. https://doi.org/10.1002/sim.1251
  25. Rayter Z, Gazet JC, Ford HT, Easton DF, Commbes RC (1990). The Comparison of conservative surgery and radiotherapy with mastectomy in the treatment of early breast cancer. Eur J Surg Oncal, 16, 486-92.
  26. Rafiquhhah Khan HM, Saxena A, Gabbidon K, et al (2014a). Survival analysis for white non-hispanic female breast cancer patients. Asian Pac J Cancer Prev, 15, 4049-54. https://doi.org/10.7314/APJCP.2014.15.9.4049
  27. Rafiqhullah Khan HM, Saxena A, Gabbidon K, Rana S, Uddin Ahmed N (2014). Model-based survival estimates of female breast cancer data. Asian Pac J Cancer Prev, 15, 2893-900. https://doi.org/10.7314/APJCP.2014.15.6.2893
  28. Sayehmiri K, Alimoghaddam K, Ghavamzadeh A (2010). Comparision of prognostic factors and death hazard function of acute myeloid leukemia and acute lymphoblastic leukemia patients after bone marrow transplanation. Int J Hematol Oncol Stem Cell Res, 4, 19-28.
  29. Saha A, Ghosh SK, Roy C, et al (2013). Demographic and Clinical profile of patients with brain metastases: A retrospective study. Asian J Neurosurg, 8, 151-61.
  30. Tsan garis TN, Knox SM, Cheek JH (1992). Tumor Hormon receptor statue and recurrences in premenopausal patients with node-negative Breast carcinoma. Cancer, 69, 984-7. https://doi.org/10.1002/1097-0142(19920215)69:4<984::AID-CNCR2820690425>3.0.CO;2-C
  31. Tewsend M, Neauchamp R, Daniel SB, Matto X, Kenneth L (2004). Sabiton text book of surgery. 17th ed. Amesterdam; Elsevier.
  32. Tripsianis G, Papadopoulou E, Romanidis K, et al (2013). Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-${\alpha}$ and TGF-${\beta}1$. Asian Pac J Cancer Prev, 14, 6813-20. https://doi.org/10.7314/APJCP.2013.14.11.6813
  33. Thakur S, Singla A, Chen J, et al (2014). Reduced ING1 levels in breast cancer promotes metastasis. Oncotarget, 1-13.
  34. Wolberg WH, Street WN, Mngasarian OL (1999). Importance of nuclear morphology in breast cancer prognosis. Clin Cancer Res, 5, 3542-48
  35. Wei XQ, Li X, Xin XJ, Tong ZS, Zhang Sh (2013). Clinical features and survival analysis of very young (age<35) breast cancer patients. Asian Pac J Cancer Prev, 14, 5949, 52.

피인용 문헌

  1. Survival Time and Molecular Subtypes of Breast Cancer after Radiotherapy in Thailand vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10505
  2. Correlation Between Mammograghic Findings and Clinical/Pathologic Features in Women with Small Invasive Breast Carcinomas vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10643
  3. Prognostic Factors for Survival in Patients with Breast Cancer Referred to Omitted Cancer Research Center in Iran vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.5081
  4. Survival Rates for Breast Cancer in Iranian Patients: a Meta-Analysis vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2223
  5. HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma-not otherwise specified vol.16, pp.4, 2017, https://doi.org/10.3892/mmr.2017.7131
  6. Expression of Breast Cancer Subtypes Based on the Most Important Biomarkers: Comparison of Clinicopathological Factors and Survival vol.20, pp.1, 2018, https://doi.org/10.5812/ircmj.57931